132307-50-7

Basic information

• Product Name: FMOC-LYS(BOC)-OSU
• Synonyms: FMOC-LYS(BOC)-OSU;FMOC-LYSINE(NICOTINOYL)-OH;FMOC-LYS(NIC)-OH;FMOC-LYS(NICOTINYL)-OH;FMOC-LYS(NICOT)-OH;FMOC-N-EPSILON-NICOTINOYL-L-LYSINE;FMOC-N-EPSILON-BOC-L-LYSINE N-HYDROXYSUCCINIMIDE ESTER;FMOC-L-LYS(NIC)-OH
• CAS NO: 132307-50-7
• Molecular Formula: C₃₀H₃₅N₃O₈
• Molecular Weight: 565.61
• Product Categories: Amino Acid Derivatives;Amino Acids
• Mol File: 132307-50-7.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Density: 1.31±0.1 g/cm3(Predicted)
• Storage Temp.: -15°C
• Solubility: Chloroform (Slightly), Dimethylformamide (Slightly, Heated, Sonicated)
• PKA: 10.13±0.46(Predicted)
• CAS DataBase Reference: FMOC-LYS(BOC)-OSU(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-LYS(BOC)-OSU(132307-50-7)
• EPA Substance Registry System: FMOC-LYS(BOC)-OSU(132307-50-7)

Safety Data

• Hazardous Substances Data: 132307-50-7(Hazardous Substances Data)

Usage

General Description

FMOC-LYS(BOC)-OSU is a chemical compound used in peptide synthesis. It is a derivative of lysine that contains a fluorophore (FMOC) and a protecting group (BOC). The FMOC group is used to monitor the progress of the peptide synthesis, while the BOC group is used to protect the lysine amino group from unwanted reactions. The OSU group is a reactive functional group that allows for the attachment of the lysine derivative to a solid support during peptide synthesis. Overall, FMOC-LYS(BOC)-OSU is a valuable tool in the development of peptides for various research and therapeutic applications.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 71989-26-9 Fmoc-Lys(tert-butoxycarbonyl) 
• 74124-79-1 di(succinimido) carbonate 

Downstream Products

• 250695-63-7 Fmoc-Lys(Boc)-Leu-OH 
• 1278592-50-9 Nα-(4-nitrobenzoyl)-Nε-Boc-lysylalanylalanine methyl ester 
• 1278592-44-1 Nα-(4-nitrobenzoyl)-Nε-thioacetyllysylalanylalanine methyl ester 
• 198561-38-5 (S)-(9H-fluoren-9-yl)methyl6-((tert-butoxycarbonyl)amino)-1-hydroxyhexan-2-ylcarbamate 

Relevant articles and documents

An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy

The 18-membered macrocycle H2macropa was investigated for 225Ac chelation in targeted alpha therapy (TAT). Radiolabeling studies showed that macropa, at submicromolar concentration, complexed all 225Ac (26 kBq) in 5 min at RT. [225Ac(macropa)]+ remained intact over 7 to 8 days when challenged with either excess La3+ ions or human serum, and did not accumulate in any organ after 5 h in healthy mice. A bifunctional analogue, macropa-NCS, was conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070. Both constructs rapidly radiolabeled 225Ac in just minutes at RT, and macropa-Tmab retained >99 % of its 225Ac in human serum after 7 days. In LNCaP xenograft mice, 225Ac-macropa-RPS-070 was selectively targeted to tumors and did not release free 225Ac over 96 h. These findings establish macropa to be a highly promising ligand for 225Ac chelation that will facilitate the clinical development of 225Ac TAT for the treatment of soft-tissue metastases.

Site-Specific Incorporation of Multiple Thioamide Substitutions into a Peptide Backbone via Solid Phase Peptide Synthesis

Among various peptide modification strategies, thioamide substitution by replacing the carbonyl oxygen atom of an amide bond with a sulfur atom constitutes an invaluable tool for chemical biology, for use in peptide drug discovery and protein structure-fu

MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by